Navigation Links
Diagnostic imaging increases among stage IV cancer patients on Medicare
Date:7/30/2012

The use of diagnostic imaging in Medicare patients with stage IV cancer has increased faster than among those with early-stage (stages I and II) disease, according to a study published July 30 in the Journal of the National Cancer Institute.

The costs of diagnostic imaging have increased more rapidly than the overall costs of cancer care, making diagnostic imaging the fastest-growing division of Medicare-reimbursed services. The net costs of cancer care are the highest in the last year of life; yet little is known about the use of high-cost imaging in cancer patients during the last year of life.

In order to determine the usage of high-cost imaging in cancer patients at the end of life, Yue-Yung Hu, M.D., M.P.H. and colleagues in the Center for Outcomes and Policy Research at Dana-Farber Cancer Institute, the Center for Surgery and Public Health at Brigham and Women's Hospital, and Wisconsin Surgical Outcomes Research Program at the University of Wisconsin, looked at claims within the Surveillance, Epidemiology, and End Results (SEER)-Medicare database between 1994 and 2009 for computed tomography, magnetic resonance imaging, positron emission tomography, and nuclear medicine scans for patients diagnosed with stage IV breast, colorectal, lung, or prostate cancer between 1995-2006. The rate of imaging per-patient per-month of survival was determined for each phase of care. For reference, trends in imaging use in early-stage patients with the same tumor types during the same time period were also considered.

The researchers found that most patients with stage IV breast, colorectal, lung, and prostate cancer undergo high-cost imaging procedures throughout the course of their care and that the usage of imaging has steadily increased between 1995 and 2006. The increase may reflect a lack of guidelines in this area or the use of imaging to guide symptom management, detect disease progression and assess treatment effect. "Because scans help clinicians determine whether a change in (or cessation of) treatment is indicated, the expanding use of advanced imaging in stage IV disease is likely a manifestation of the increasing number and types of treatment options available to these patients," the authors write. "Imaging, although it often leads to (appropriate) palliative measures, may also distract patients from focusing on achievable end-of-life goals, require them to spend more of their limited time in medical care settings and/or provoke anxiety." The authors point out the importance of examining such patient-centered outcomes in future research to define the role of advance imaging in Stage IV solid tumors.

In an accompanying editorial, Drs. Robin Yabroff and Joan Warren, of the Health Services and Economics Branch at the National Cancer Institute, feel that assessing the appropriateness of care for patients with stage IV disease is complex. "Physicians tend to overestimate survival for terminally ill cancer patients, which may influence their treatment and related imaging recommendations," the editorialists write. "Development of practice guidelines for advanced imaging in patients with stage IV disease, with explicit statements about the state of evidence will be critical, particularly for care outside of the window surrounding patient diagnosis."


'/>"/>

Contact: Zachary Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
2. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
3. Diagnostic yield of colonoscopy for melena after nondiagnostic upper endoscopy is lower than previously reported
4. Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
5. Screening for breast cancer without X-rays: Lasers and sound merge in promising diagnostic technique
6. A marker in the lining of the lungs could be useful diagnostic technique for lung cancer screening
7. UGA researchers develop rapid diagnostic test for pathogens, contaminants
8. AMA adopts diagnostic ultrasound utilization and education resolution
9. A new genre of diagnostic tests for the era of personalized medicine
10. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
11. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... ... ... who like to educate themselves on current issues and who enjoy gaining knowledge on ... to appreciate and love the "Informed" series, hosted by Rob Lowe. A new ... the world. , Running for charity has become a multi-million dollar enterprise ...
(Date:3/24/2017)... ... 24, 2017 , ... Judy Buchanan, co-owner of Serenity Natural ... Judy says, “I am passionate about sharing Reiki as a holistic, complementary therapy ... challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization ... could be four million Zika-related cases in the Americas within the next year. Lyme ... cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)...  HealthMine surveys with 9,250 insured consumers fielded from ... members want help from their plans in five key ... health, 2) help closing gaps in care, 3) better ... 5) relevant, real-time guidance. Meeting these needs is essential ... A Reason to Stay Engaged in ...
(Date:3/24/2017)... 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today disclosed ... Term Sheet (the "Definitive Financing") it entered into ... Company,s stockholders, who are referred to in the ... 8-K filed with the Securities and Exchange Commission. ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA ... the complete 2016 Annual Accounts with notes. The report is ... in the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, ... Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media ...
Breaking Medicine Technology: